Original article| Volume 44, 102264, September 2020

Connection of miR-185 and miR-320a expression levels with response to interferon-beta in multiple sclerosis patients


      • miR- 185–5p was downregulated in responder patients relative to non-responders.
      • MAPK signaling was predicted as an important pathway in interferon-beta signaling.
      • miR-185–5p can be considered as a novel biomarker for therapy response.



      Multiple sclerosis (MS) is an inflammatory autoimmune disease characterized by neurodegeneration in the CNS. Interferon-beta (IFN-β) is an FDA-approved drug used as the first-line treatment for relapse-remitting multiple sclerosis (RRMS). The exact mechanism of IFN-β during the treatment of RRMS still remains unknown. Recently, many studies have shifted towards the role of miRNAs in the treatment of MS patients.


      Herein, the expression level of miR-185–5p and miR-320a has been evaluated in order to candidate them as novel biomarkers for monitoring the response to IFN-β therapy. For this purpose, one-hundred whole blood samples from patients with RRMS were collected, consisting of 50 responders and 50 non-responders to IFN-β therapy. To predict the possible molecular mechanisms of IFN-β and highlight the role of these miRNAs, in silico analysis was applied to enrich the signaling pathways which may be involved based on the target genes of miR-185–5p and miR-320a.


      It is identified that the differentially expressed miR-185–5p was statistically significant between the two treated groups with IFN-β. Furthermore, MAPK signaling pathway was suggested as the main non-canonical pathway involved in IFN-β therapy.


      miR-185–5p could be considered as a novel biomarker for monitoring the response to IFN-β therapy.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Baulina N.
        • Kulakova O.
        • Kiselev I.
        • Osmak G.
        • Popova E.
        • Boyko A.
        • Favorova O.
        Immune-related miRNA expression patterns in peripheral blood mononuclear cells differ in multiple sclerosis relapse and remission.
        J. Neuroimmunol. 2018; 317: 67-76
        • Chou C.-.H.
        • Shrestha S.
        • Yang C.-.D.
        • Chang N.-.W.
        • Lin Y.-.L.
        • Liao K.-.W.
        • Huang W.-.C.
        • Sun T.-.H.
        • Tu S.-.J.
        • Lee W.-.H.
        miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions.
        Nucleic. Acids Res. 2017; 46: D296-D302
        • Dobson R.
        • Giovannoni G.
        Multiple sclerosis–a review.
        Eur. J. Neurol. 2019; 26: 27-40
        • Dupont W.D.
        • Plummer JR, W.D.
        Power and sample size calculations for studies involving linear regression.
        Control. Clin. Trials. 1998; 19: 589-601
        • Dweep H.
        • Gretz N.
        miRWalk2. 0: a comprehensive atlas of microRNA-target interactions.
        Nat. Methods. 2015; 12: 697
        • Dweep H.
        • Sticht C.
        • Pandey P.
        • Gretz N.
        miRWalk–database: prediction of possible miRNA binding sites by “walking” the genes of three genomes.
        J. Biomed. Inform. 2011; 44: 839-847
        • Ehtesham N.
        • Khorvash F.
        • Kheirollahi M.
        miR-145 and miR20a-5p potentially mediate pleiotropic effects of interferon-beta through mitogen-activated protein kinase signaling pathway in multiple sclerosis patients.
        J. Mol. Neurosci. 2017; 61: 16-24
        • Fattahi M.
        • Rezaei N.
        • Nematalahi F.S.
        • Shaygannejad V.
        • Fouladi S.
        • Karimi L.
        • Fathi F.
        • Dehghani L.
        • Mirmosayyeb O.
        • Eskandari N.
        MicroRNA-29b variants and MxA expression change during interferon beta therapy in patients with relapsing-remitting multiple sclerosis.
        Mult. Scler. Relat. Disord. 2019; 35: 241-245
        • Hecker M.
        • Hartmann C.
        • Kandulski O.
        • Paap B.K.
        • Koczan D.
        • Thiesen H.-.J.
        • Zettl U.K.
        Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients’ individual gene expression in peripheral blood.
        Mol. Neurobiol. 2013; 48: 737-756
        • Hecker M.
        • Thamilarasan M.
        • Koczan D.
        • Schröder I.
        • Flechtner K.
        • Freiesleben S.
        • Fullen G.
        • Thiesen H.-.J.
        • Zettl U.
        MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients.
        Int. J. Mol. Sci. 2013; 14: 16087-16110
        • Huang D.W.
        • Sherman B.T.
        • Lempicki R.A.
        Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists.
        Nucleic. Acids Res. 2008; 37: 1-13
        • Huang D.W.
        • Sherman B.T.
        • Lempicki R.A.
        Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.
        Nat. Protoc. 2009; 4: 44
        • Kanehisa M.
        • Goto S.
        KEGG: kyoto encyclopedia of genes and genomes.
        Nucleic Acids Res. 2000; 28: 27-30
        • Kanehisa M.
        • Sato Y.
        • Furumichi M.
        • Morishima K.
        • Tanabe M.
        New approach for understanding genome variations in KEGG.
        Nucleic Acids Res. 2018; 47: D590-D595
        • Killestein J.
        • Polman C.H.
        Determinants of interferon β efficacy in patients with multiple sclerosis.
        Nat. Rev. Neurol. 2011; 7: 221
        • Leray E.
        • Moreau T.
        • Fromont A.
        • Edan G.
        Epidemiology of multiple sclerosis.
        Rev. Neurol. (Paris). 2016; 172: 3-13
        • Liguori M.
        • Nuzziello N.
        • Licciulli F.
        • Consiglio A.
        • Simone M.
        • Viterbo R.G.
        • Creanza T.M.
        • Ancona N.
        • Tortorella C.
        • Margari L.
        Combined microRNA and mRNA expression analysis in pediatric multiple sclerosis: an integrated approach to uncover novel pathogenic mechanisms of the disease.
        Hum. Mol. Genet. 2017; 27: 66-79
        • Lublin F.D.
        • Reingold S.C.
        • Cohen J.A.
        • Cutter G.R.
        • Sørensen P.S.
        • Thompson A.J.
        • Wolinsky J.S.
        • Balcer L.J.
        • Banwell B.
        • Barkhof F.
        Defining the clinical course of multiple sclerosis: the 2013 revisions.
        Neurology. 2014; 83: 278-286
        • Magner W.J.
        • Weinstock-Guttman B.
        • Rho M.
        • Hojnacki D.
        • Ghazi R.
        • Ramanathan M.
        • Tomasi T.B.
        Dicer and microRNA expression in multiple sclerosis and response to interferon therapy.
        J. Neuroimmunol. 2016; 292: 68-78
        • Marzullo A.
        • Kocevar G.
        • Stamile C.
        • Durand-Dubief F.
        • Terracina G.
        • Calimeri F.
        • Sappey-Marinier D.
        Classification of multiple sclerosis clinical profiles via graph convolutional neural networks.
        Front. Neurosci. 2019; 13
        • Murdoch D.
        • Lyseng-Williamson K.A.
        Spotlight on subcutaneous recombinant interferon-β-1a (Rebif®) in relapsing-remitting multiple sclerosis.
        Bio.Drugs. 2005; 19: 323-325
        • Nuzziello N.
        • Vilardo L.
        • Pelucchi P.
        • Consiglio A.
        • Liuni S.
        • Trojano M.
        • Liguori M.
        Investigating the role of microRNA and transcription factor co-regulatory networks in multiple sclerosis pathogenesis.
        Int. J. Mol. Sci. 2018; 19: 3652
        • Platanias L.C.
        Mechanisms of type-I-and type-II-interferon-mediated signalling.
        Nat. Rev. Immunol. 2005; 5: 375
        • Regev K.
        • Paul A.
        • Healy B.
        • Von Glenn F.
        • Diaz-Cruz C.
        • Gholipour T.
        • Mazzola M.A.
        • Raheja R.
        • Nejad P.
        • Glanz B.I.
        Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis.
        Neurol.-Neuroimmunol. Neuroinflammation. 2016; 3: e267
        • Río J.
        • Nos C.
        • Tintore M.
        • Tellez N.
        • Galán I.
        • Pelayo R.
        • Comabella M.
        • Montalban X.
        Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patients.
        Ann. Neurol.: Off. J. Am. Neurol. Assoc. Child Neurol. Soc. 2006; 59: 344-352
        • Rudick R.A.
        • Goelz S.E.
        Beta-interferon for multiple sclerosis.
        Exp. Cell Res. 2011; 317: 1301-1311
        • Shannon P.
        • Markiel A.
        • Ozier O.
        • Baliga N.S.
        • Wang J.T.
        • Ramage D.
        • Amin N.
        • Schwikowski B.
        • Ideker T.
        Cytoscape: a software environment for integrated models of biomolecular interaction networks.
        Genome Res. 2003; 13: 2498-2504
        • Singh M.K.
        • Scott T.F.
        • Laframboise W.A.
        • Hu F.Z.
        • Post J.C.
        • Ehrlich G.D.
        Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy.
        J. Neurol. Sci. 2007; 258: 52-59
        • Teymoori-Rad M.
        • Mozhgani S.H.
        • Zarei-Ghobadi M.
        • Sahraian M.A.
        • Nejati A.
        • Amiri M.M.
        • Shokri F.
        • Marashi S.M.
        Integrational analysis of miRNAs data sets as a plausible missing linker between Epstein-Barr virus and vitamin D in relapsing remitting MS patients.
        Gene. 2019; 689: 1-10
        • Traboulsee A.
        • Li D.K.
        • Cascione M.
        • Fang J.
        • Dangond F.
        • Miller A.
        Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing–remitting multiple sclerosis at year 1.
        BMC Neurol. 2018; 18: 143
        • Yasuda S.
        • Sugiura H.
        • Tanaka H.
        • Takigami S.
        • Yamagata K.
        p38 MAP kinase inhibitors as potential therapeutic drugs for neural diseases.
        Cent. Nerv. Syst. Agents Med. Chem. (Former. Curr. Med. Chem.-Cent. Nerv. Syst. Agents). 2011; 11: 45-59